Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $37,649.64 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,862 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $20.22, for a total value of $37,649.64. Following the transaction, the insider owned 51,391 shares in the company, valued at $1,039,126.02. This represents a 3.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Monday, February 23rd, Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $15.57, for a total value of $61,890.75.

KalVista Pharmaceuticals Stock Up 0.7%

KalVista Pharmaceuticals stock opened at $19.56 on Thursday. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $21.31. The stock has a 50 day moving average of $17.67 and a two-hundred day moving average of $15.31. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -4.95 and a beta of -0.40.

Analyst Upgrades and Downgrades

KALV has been the subject of a number of recent research reports. Needham & Company LLC increased their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. Wall Street Zen cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, HC Wainwright increased their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.60.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $24,360,000. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after buying an additional 313,205 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $3,494,000. Blue Owl Capital Holdings LP acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $1,522,000. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in shares of KalVista Pharmaceuticals by 19.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock valued at $11,181,000 after buying an additional 149,003 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.